AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04581967
Drug: Doxorubicin-Cyclophosphamide regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with a combination of Doxorubicin and Cyclophosphamide, This regimen comprises 60 mg/m² Doxorubicin and 600 mg/m² Cyclophosphamide administered intravenously on day 1 of each 21-day cycle, and repeated for a total of four cycles.
Trial: NCT00264537
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injections
Trial: NCT00264537
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be filled with microcrystalline cellulose (Avicel PH 102).
Trial: NCT00264537
Drug: Methotrexate capsules
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate capsules will be filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg methotrexate tablet.
Trial: NCT03790059
Drug: H101
RxNorm normalized name: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative injection of H101 can improve the efficacy of RFA in hepatocellular carcinoma.
Trial: NCT00636285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00636285
Drug: BSYX-A110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSYX-A110, Dosed intravenously, 3 mg/kg
Trial: NCT00636285
Drug: BSYX-A110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSYX-A110, Dosed intravenously, 10 mg/kg
Trial: NCT00853151
Drug: LY2428757
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mg subcutaneous injection 1 time a week for 5 weeks
Trial: NCT00853151
Drug: Placebo for LY2428757
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection 1 time a week for 5 weeks
Trial: NCT00853151
Drug: Placebo for TT223
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection once a day for 4 weeks
Trial: NCT02221232
Drug: ZuraPrep
RxNorm normalized name: DuraPrep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically.
Trial: NCT02221232
Drug: ZuraPrep Vehicle
RxNorm normalized name: DuraPrep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically.
Trial: NCT01504412
Drug: DS-5565
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered twice daily
Trial: NCT01504412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day
Trial: NCT03607123
Drug: Anti arryhthmic drugs
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti arryhthmic drugs can be prescribed in Step 2, Step3 and SAFE PAF-SND
Trial: NCT01338129
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pills
Trial: NCT04004429
Drug: 50 mg AP1189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg AP1189 powder in bottle
Trial: NCT04004429
Drug: AP1189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg AP1189 powder in bottle
Trial: NCT04004429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo powder in bottle
Trial: NCT00631189
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5mg oral
Trial: NCT00631189
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg oral
Trial: NCT02135549
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT04611061
Drug: Kagocel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators could prescribe other drugs in frame of routine clinical practice
Trial: NCT04611061
Drug: No one
RxNorm normalized name: ALCOHOL 70 g in 100 mL TOPICAL GEL [d.therapino one step hand sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
Trial: NCT00117299
Drug: PTK787/ZK222584
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally
Trial: NCT01520350
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03199417
Drug: Multiprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel.
Trial: NCT01063829
Drug: 60 mg AIC246
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT01063829
Drug: 120 mg AIC246
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT01063829
Drug: 240 mg AIC246
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT00134017
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -3, -2, +3, +4: 50 mg/kg IV daily
Trial: NCT02862327
Drug: intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection of placebo
Trial: NCT04304534
Drug: BAY2433334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, taken orally once a day.
Trial: NCT03313856
Drug: Guazuma Ulmifolia plus Tecoma Stans
RxNorm normalized name: Guazuma ulmifolia leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guazuma ulmifolia (313.6 mg) -Tecoma stans (86.4 mg) = 400 mg per capsule
Trial: NCT03255642
Drug: Melatonin 2mg
RxNorm normalized name: Vicks ZzzQuil PURE Zzzs Melatonin 2mg Extended-Release Tablet
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 weeks of 2mg prolonged release melatonin (Circadin)
Trial: NCT01501435
Drug: CJ-30039
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT01304602
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120, oral, daily starting with cycle 1/day 2 at the cohort defined dose level
Trial: NCT04522167
Drug: Eylea® (Aflibercept)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 1 IVT injection of Eylea® every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
Trial: NCT01368809
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
Trial: NCT00819884
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension
Trial: NCT02801565
Drug: Conventional controlled ovarian stimulation proctol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional controlled ovarian stimulation proctol without rhGH.
Trial: NCT04279535
Drug: Topical Ascorbic Acid
RxNorm normalized name: ascorbic acid Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.
Trial: NCT01131845
Drug: UT-15C SR (treprostinil diethanolamine)
RxNorm normalized name: Diethanolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, 1 mg UT-15C SR
Trial: NCT02054299
Drug: Drug application Thiamine
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamine: 200mg, single oral application
Trial: NCT01833065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00507637
Drug: NT 201
RxNorm normalized name: Fluarix Quadrivalent 2013-2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of up to 50 Units NT 201 (incobotulinumtoxinA/Xeomin®) per eye and injection visit (8 injections visits in total).
Trial: NCT01834235
Drug: NPC-1C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 28 day cycle. This will be administered 30 minutes after completion of the gemcitabine infusion.
Trial: NCT01923649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for somatuline slow release 90 mg
Trial: NCT00001212
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01224717
Drug: PTH134
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01224717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01564875
Drug: Simvast CR
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
Trial: NCT00543725
Drug: TMC278
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tablet once daily for 96 weeks
Trial: NCT02630472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In order to blind the participants to which arm they have been randomized into, the placebo arm will contain saline solution spiked with 0.5 mg/ml sucrose octaacetate. This solution will produce a bitter flavor similar to the one produced by quinine. There is no evidence that sucrose octaacetate produces nitric oxide production in the sinonasal cavity, nor is there evidence that it has any side effects (it is used to wean babies off of pacifiers) so the investigators feel it is an effective and safe option for a placebo.
Trial: NCT00002984
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU will be given at 500 mg/m2 in 1 liter D5 1/2 by continuous infusion every 12 hours for a total of 8 doses (Total 1.0 g/m2/day X 4 days) on Days 1-4 and 29-32 for a total of 2 courses
Trial: NCT03777085
Drug: TQB2303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
Trial: NCT01423292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00845845
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo with dietary counseling for 24 weeks.
Trial: NCT02169713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03242590
Drug: LPCN 1021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate
Trial: NCT02398604
Drug: Allo-hMSCs
RxNorm normalized name: allo-2-hydroxycitric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic Human Mesenchymal Stem Cells
Trial: NCT02398604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00412243
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Beginning dose 200 mg/m\^2 every 12 hours for 3 days
Trial: NCT01674569
Drug: X-82 oral
RxNorm normalized name: Gas-X Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: X-82 oral for 24 weeks or until unacceptable toxicity develops
Trial: NCT01026142
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 po twice daily for 14 days every 3 weeks
Trial: NCT03316638
Drug: W0101 - Cohort A2
RxNorm normalized name: PROCYANIDIN A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered every 3 weeks
Trial: NCT03316638
Drug: W0101 - Expansion Phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered according to the recommended dose for expansion
Trial: NCT03014687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO BID placebo for 7 days. Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
Trial: NCT02228811
Drug: DCC-2701 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02824003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once weekly dosing for 13 weeks
Trial: NCT00567164
Drug: EE20/DRSP (BAY86-5300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
Trial: NCT00567164
Drug: EE20/DRSP (YAZ, BAY86-5300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
Trial: NCT03383887
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo before sleep
Trial: NCT03383887
Drug: DAW1033D oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAW1033D before sleep
Trial: NCT03736785
Drug: LY3209590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02974010
Drug: Saline Solution Intravenous Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
Trial: NCT01594502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT02837380
Drug: VI/UMEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VI and UMEC bromide combination is a dry white powder blended with lactose and magnesium stearate. It is the second strip of DPI. Per blister contains 25 mcg/62.5 mcg of VI/UMEC dose
Trial: NCT02805244
Drug: JTZ-951, 14C-JTZ-951
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02952755
Drug: Co-administration of DWC20155/DWC20156
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02952755
Drug: DWC20162
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01026142
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m2 po twice daily for 14 days every 3 weeks
Trial: NCT00413790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily
Trial: NCT03681951
Drug: GSK3145095
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3145095 will be available as capsule (size 1 containing 5 to 25 mg GSK3145095 and size 0 containing 25 to 75 mg GSK3145095) or tablet (25, 50, 200 mg white to slightly covered round/oval shaped coated) for oral administration in the fasted stated with approximately 200 milliliters (mL) of water.
Trial: NCT00628251
Drug: AZD2281
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg Oral twice daily
Trial: NCT00628251
Drug: Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg/m2 Monthly Intravenous
Trial: NCT00628251
Drug: AZD2281
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg oral twice daily
Trial: NCT00002863
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01501214
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline given
Trial: NCT00990678
Drug: Calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, 400 mg calcium, 3 times daily
Trial: NCT02073682
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic doses of subcutaneous LMWH were administered for at least 5 days (to patients in the edoxaban group); this 5-day period may have included the pre-randomization LMWH (if applicable). The choice of parenteral LMWH was up to the treating physician.
Trial: NCT01638624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00089037
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004030
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01191957
Drug: Busulphan plus Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. Bu (Busilvex), 12.8 mg/kg:~Day -9: 0.8 mg/kg/dose x 4 doses Day -8: 0.8 mg/kg/dose x 4 doses Day -7: 0.8 mg/kg/dose x 4 doses Day -6: 0.8 mg/kg/dose x 4 doses Day -5: Rest~Followed by:~Cyclophosphamide, 120 mg/kg iv:~Day -4: 60 mg/kg Day -3: 60 mg/kg
Trial: NCT01965704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All doses of placebo, whether IV or oral, will mimic the same volume as the ondansetron group to maintain the blind. Pregnant women may receive a second dose of IV placebo if they have not delivered within 4 hours of being given the IV study medication. 50% of the 90 mother/baby pairs will receive placebo; the baby will always receive the same study medication as the mother.
Trial: NCT04930952
Drug: Ethanol-amine Oleate Sclerotherapy Injection
RxNorm normalized name: Ethanolamine Oleate
DrugBank: Ethanolamine oleate (DB06689)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intralesional Sclerotherapy Injection
Trial: NCT00004360
Drug: chlorothiazide
RxNorm normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00081744
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01311895
Drug: 1+1
RxNorm normalized name: Prenazyme 1+1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?
Trial: NCT00837213
Drug: Benzoyl peroxide with clindamycin
RxNorm normalized name: benzoyl peroxide / clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide wash - Clindamycin foam
Trial: NCT00837213
Drug: Benzoyl peroxide with clindamycin and doxycycline
RxNorm normalized name: benzoyl peroxide / clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide wash - Clindamycin foam - Doxycycline capsules
Trial: NCT02195375
Drug: Flutiform 500/20 µg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02195375
Drug: Flutiform 250/10 µg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02195375
Drug: Seretide Accuhaler 50/500 µg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02648425
Drug: ASLAN001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
Trial: NCT02648425
Drug: cisplatin + capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
Trial: NCT02648425
Drug: cisplatin + 5-fluorouracil (or+ Leucovorin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;~Or~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks.
Trial: NCT01723670
Drug: CHF 5074 2x
RxNorm normalized name: Worm Protector 2X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, 2x, once a day for 24 months
Trial: NCT01723670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet,once a day for 24 months
Trial: NCT02915263
Drug: IGIV-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
Trial: NCT01069965
Drug: Placebo BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two Placebo capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
Trial: NCT01295593
Drug: valproic acid and 2-chlorodeoxyadenosine
RxNorm normalized name: 2-Chlorodeoxyadenosine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA : daily, oral, starting dose 10mg/kg/day total dose, taken in 2 separate administrations of around 5 mg/kg/day each, for a maximum of 6 months CdA : 5.6 mg/m²/day IV during 3 days, every 28 days, for a maximum of 4 cycles
Trial: NCT04709094
Drug: Ethinyl Estradiol/Norethindrone
RxNorm normalized name: ETHINYL ESTRADIOL/NORETHINDRONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/NET (0.035 mg/1 mg) was dosed as Ortho-Novum-1/35 (or generic equivalent) fixed-dose combination tablets.
Trial: NCT02376972
Drug: PLACEBO VAGINAL TABLET
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY
Trial: NCT02376972
Drug: METROGEL VAGINAL
RxNorm normalized name: MetroGel Vaginal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY
Trial: NCT04370288
Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A mixture of MCN will be injected to covid-19 patients.
Trial: NCT01266525
Drug: SAR110894
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Capsule~Route of administration: Oral
Trial: NCT01266525
Drug: placebo (for SAR110894)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Capsule~Route of administration: Oral